Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

Sept. 16, 2024 – Tiny bottles of the weight loss drug Zepbound have started arriving in mailboxes across the country. People who order the medicine directly from drugmaker Eli Lilly can pay much ...

The drugs, sold as Mounjaro and Zepbound, are both made from the active ingredient tirzepatide, which has been on the FDA’s shortage list for almost two years. The FDA’s announcement comes two ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval. All doses of tirzepatide ...

Zepbound (tirzepatide) is a prescription drug that’s used for weigh loss in certain adults. The drug comes as a liquid solution inside prefilled injection pens. Zepbound is not safe to use while ...